Hepatitis C accounted for a 0.9% share of the global clinical trials within the Infectious Disease therapy area in 2020, registering a decrease of 10.4% when compared with the last ten-year average of 11.3% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Hepatitis C
Industry sponsored trials held a 55.6% share of all the clinical trials for Hepatitis C indication in 2020, registering an increase of 6.1% when compared with the ten-year average of 49.5%. Non-industry sponsored trials accounted for a 44.4% share in 2020, marking a decrease of 6.1% over the ten-year average of 50.5%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Hepatitis C trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Hepatitis C trials, accounting for a 63.6% share in 2020, when compared with the five-year average of 61.7% and ten-year average of 47.5%.
Europe was at the second position with a 31.8% share in 2020, over the five-year average of 33.4% and ten-year average of 39.4%, followed by North America with a 9.1% share in 2020, as against five-year and ten-year averages of 26.8% and 43.0% respectively.
South and Central America stood fourth with a 0.0% share in 2020, compared with the five-year average of 1.3% and ten-year average of 4.0%, followed by Middle East and Africa with a 0.0% share in 2020, over five-year and ten-year averages of 7.7% and 7.4% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Hepatitis C trials, accounting for a 45.5% share in 2020, as against the five-year average of 30.1% and ten-year average of 16.5%.
Russia held a 22.7% share in 2020, over the five-year average of 10.4% and ten-year average of 9.7%, followed by Australia with a 9.1% share in 2020, compared with the five-year and ten-year averages of 8.0% and 11.1% respectively.
Belgium held a 4.5% share in 2020, as against the five-year average of 7.9% and ten-year average of 10.3%.
Canada held a 4.5% share in 2020, over the five-year and ten-year averages of 10.9% and 13.1% respectively.
Top regions of non-industry sponsored Hepatitis C trials
Asia-Pacific was the top region for non-industry sponsored Hepatitis C trials, accounting for a 44.4% share in 2020 when compared with the five-year average of 42.9% and ten-year average of 43.0%.
North America was at the second position with a 38.9% share in 2020, over the five-year and ten-year averages of 23.1% and 23.4% respectively, followed by Middle East and Africa with a 16.7% share in 2020, as against the five-year average of 19.0% and ten-year average of 12.1%.
South and Central America stood at the fourth position with a 0.0% share in 2020, compared with the five-year average of 1.1% and ten-year average of 1.5%, followed by Europe with a 0.0% share in 2020, over the five-year and ten-year averages of 16.9% and 21.7% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for non-industry sponsored Hepatitis C trials, accounting for a 38.9% share in 2020, as against the five-year average of 21.4% and ten-year average of 21.0%.
China held a 16.7% share in 2020, over the five-year average of 8.6% and ten-year average of 7.1%, followed by Egypt with a 16.7% share, compared with the five-year and ten-year averages of 14.1% and 8.4% respectively.
Australia held a 5.6% share in 2020, as against the five-year average of 3.9% and ten-year average of 3.1%.
Myanmar held a 5.6% share in 2020, over the five-year average of 0.5% and ten-year average of 0.2%.
Phase I trials lead industry sponsored clinical trials for Hepatitis C in 2020
Phase I trials held a 68.0% share of industry sponsored clinical trials for Hepatitis C in 2020, over the five-year average of 34.8% and ten-year average of 38.5%.
Phase IV trials held a 16.0% share in 2020, as against the five-year average of 23.2% and ten-year average of 15.0%. Phase II trials held a 12.0% share in 2020, compared with the five-year and ten-year averages of 21.7% and 25.9% respectively.
Phase III trials held a 4.0% share in 2020, over the five-year average of 20.3% and ten-year average of 20.6%.
Phase IV trials lead non-industry sponsored clinical trials for Hepatitis C in 2020
Phase IV trials held a 60.0% share of non-industry sponsored clinical trials for Hepatitis C in 2020, over the five-year average of 45.8% and ten-year average of 39.2%.
Phase I trials held a 20.0% share in 2020, as against the five-year average of 6.7% and ten-year average of 7.8%. Phase II trials held a 20.0% share, compared with the five-year and ten-year averages of 35.0% and 40.0% respectively.
Phase III trials held a 0.0% share in 2020, over the five-year average of 12.5% and ten-year average of 12.9%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
